Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Non-Current Liabilities (2020 - 2023)

Historic Other Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to $305.3 million.

  • ADC Therapeutics' Other Non-Current Liabilities rose 4660.88% to $305.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $305.3 million, marking a year-over-year increase of 4660.88%. This contributed to the annual value of $838000.0 for FY2022, which is 28323.64% up from last year.
  • Per ADC Therapeutics' latest filing, its Other Non-Current Liabilities stood at $305.3 million for Q3 2023, which was up 4660.88% from $299.3 million recorded in Q2 2023.
  • ADC Therapeutics' Other Non-Current Liabilities' 5-year high stood at $305.3 million during Q3 2023, with a 5-year trough of $208.0 in Q3 2020.
  • Over the past 4 years, ADC Therapeutics' median Other Non-Current Liabilities value was $206.3 million (recorded in 2022), while the average stood at $165.4 million.
  • In the last 5 years, ADC Therapeutics' Other Non-Current Liabilities skyrocketed by 10318691923.08% in 2021 and then crashed by 298.7% in 2022.
  • ADC Therapeutics' Other Non-Current Liabilities (Quarter) stood at $208.0 in 2020, then skyrocketed by 105026.92% to $218664.0 in 2021, then skyrocketed by 283.24% to $838000.0 in 2022, then surged by 36327.92% to $305.3 million in 2023.
  • Its Other Non-Current Liabilities was $305.3 million in Q3 2023, compared to $299.3 million in Q2 2023 and $216.6 million in Q1 2023.